Table 6 The inflammatory signaling pathways and related gene transcripts affected by daily injection of PYS compared to Control
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
|---|---|---|
Granulocyte adhesion and diapedesis (1.32 × 10 −6) | SELL, VCAM1, CXCL13, CXCR2, CXCL14, CCL21, CXCL3, TNF, MMP9, CCL19, TNFRSF11B | MMP27, THY1 |
Agranulocyte adhesion and diapedesis (7.4 × 10 −5) | SELL, VCAM1, CXCL13, CXCR2, CXCL14, CCL21, CXCL3, TNF, MMP9, CCL19 | MMP27 |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.4539, NS) | TNF | – |
Acute phase response signaling (7.8 × 10 −7) | SOCS3, HP, C3, ORM1, Saa3, CFB, TNF, A2M, RBP1, FGG, TNFRSF11B | NFKBIA, CRABP1 |
Complement (0.0933, NS) | C3, CFB | – |
IL-10 signaling (0.0692, NS) | SOCS3, TNF | NFKBIA |
Differential regulation of cytokine production in MΦ and Th cell (0.2239, NS) | TNF | – |
B cell development (0.0851, NS) | – | SPN, HLA-DRA |
Inhibition of matrix metalloproteinase (0.0002) | TIMP1, A2M, MMP9 | MMP27, ADAM12, |
Cross talk between DCs and NK cells (0.0083) | TNF | HLA-DRA, CD226, HLA-E, IL4 |
TREM1 signaling (0.2818, NS) | TNF | Tlr11 |
ICOs/ICOSL signaling in Th cells (0.0912, NS) | CAMK4, PIK3C2G | NFKBIA, HLA-DRA |
Antigen presentation pathway (0.0933, NS) | – | HLA-DRA, HLA-E |
IL-6 signaling (0.0021) | SOCS3, CSNK2A1, PIK3C2G, A2M, TNF, TNFRSF11B | NFKBIA |
CD28 signaling in Th cells (0.1117, NS) | CAMK4, PIK3C2G | NFKBIA, HLA-DRA |
Toll-like receptor signaling (0.2767, NS) | TNF | NFKBIA |
IL-17 signaling in fibroblast (0.0126) | LCN2, CEBPD | NFKBIA |
MIF-mediated glucocortical regulation (0.0776, NS) | PLA2G2A | NFKBIA |
MIF regulation of innate immunity (0.0195) | NOS2, PLA2G2A | NFKBIA |
HMGB1 signaling (0.0389) | VCAM1, PIK3C2G, TNF, TNFRSF11B | IL4 |
Nur 77 signaling in T cells (0.1995, NS) | CAMK4 | HLA-DRA |